Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 66

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 66
---
 ● | HIPAA,                                                                                             
 as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH)      
 and their implementing regulations, also imposes obligations, including mandatory contractual      
 terms, on covered entities, which are health plans, healthcare clearinghouses, and certain         
 health care providers, as those terms are defined by HIPAA, and their respective business          
 associates and their subcontractors, with respect to safeguarding the privacy, security and        
 transmission of individually identifiable health information;                                      |
| ● | the                                                                                                
 federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs,        
 devices, biologics and medical supplies for which payment is available under Medicare, Medicaid    
 or the Children’s Health Insurance Program, with specific exceptions, to annually report           
 to CMS information regarding payments and other transfers of value to physicians, defined          
 to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals  
 as well as information regarding ownership and investment interests held by physicians and         
 their immediate family members. Beginning in 2022, reporting obligations with respect to           
 covered recipients will be expanded to include physician assistants, nurse practitioners,          
 clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist           
 assistants, and certified nurse midwives for payments and transfers of value made during           
 the previous year; and                                                                             |
| ● | analogous                                                                                          
 state and foreign laws and regulations, such as state anti-kickback and false claims laws,         
 may apply to sales or marketing arrangements and claims involving healthcare items or services     
 reimbursed by non-governmental third-party payors, including private insurers; state laws          
 that require pharmaceutical companies to comply with the pharmaceutical industry’s                 
 voluntary compliance guidelines and the relevant compliance regulations promulgated by the         
 federal government and may require drug manufacturers to report information related to payments    
 and other transfers of value to physicians and other healthcare providers, marketing expenditures, 
 or drug pricing; state and local laws that require the registration of pharmaceutical sales        
 and medical representatives; state laws that govern the privacy and security of health information 
 in some circumstances, many of which differ from each other in significant ways and often          
 are not preempted by HIPAA, thus complicating compliance efforts.                                  |

| 36 |

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy laws and regulations will involve substantial ongoing costs, and may require us to undertake or implement additional policies or measures. We may face claims and proceedings by private parties